retatrutide approval 2025 is the most significant weight-loss pharmaceutical currently in clinical development., Phase 3 TRIUMPH-4 trial results (published December 2025) showed average body weight reduction of Retatrutide Availability & Timeline |

Additionally, the medications effects on gastric emptying delay alcohol absorption, creating unpredictable timing of intoxication

This whole new range is aimed at supporting shoppers wellbeing in a meaningful, accessible and convenient way. These new ranges, from fast-food chains in the US and supermarkets in the UK, are proof that the GLP-1 boom is blurring the line between food and health

Trial data showed injection site reactions in about 14% of participants

Those brand-name finished drug products went through full FDA review for safety, effectiveness, quality, and manufacturing consistency

Use a fresh U-100 insulin syringe (29-31G, 0.3 mL or 0.5 mL) for measuring and injecting doses